Could cutting bladder pills boost brain health in Parkinson's?
NCT ID NCT07627529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether slowly reducing or stopping a type of bladder medication (antimuscarinics) can improve thinking and quality of life in people with Parkinson's disease. Twenty participants will go through periods of taking their usual dose and periods of tapering off, while their cognitive function and symptoms are tracked. The goal is to see if deprescribing these drugs is beneficial and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
overactive bladder antimuscarinic medication (deprescribing)
What this could lead to
If successful, this could show that reducing or stopping certain bladder medications may improve thinking and quality of life for people with Parkinson's disease.
What could go wrong
This is a very small, early-stage trial with only 20 participants. Results may not apply to everyone, and some people may experience worse bladder symptoms when reducing the medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact